Real world initiation of newly funded empagliflozin and dulaglutide under special authority for patients with type 2 diabetes in New Zealand

Abstract Background Type 2 diabetes (T2D) is sub-optimally managed for many in Aotearoa New Zealand, and disproportionately affects Māori and Pacific peoples. In February 2021, SGLT2i/GLP1RA agents were funded for use for the first time with prioritisation for Māori, Pacific and those with cardiovas...

Description complète

Détails bibliographiques

Auteurs principaux:	Lynne Chepulis, Mark Rodrigues, Han Gan, Rawiri Keenan, Tim Kenealy, Rinki Murphy, Leanne Te Karu, Jo Scott-Jones, Penny Clark, Allan Moffitt, Sara Mustafa, Ross Lawrenson, Ryan Paul
Format:	Artigo
Langue:	Inglês
Publié:	BMC 2025-03-01
Collection:	BMC Health Services Research
Sujets:	SGLT2i GLP1RA Type 2 diabetes Health system access
Accès en ligne:	https://doi.org/10.1186/s12913-025-12601-3
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!